Skip to main content
Log in

Strategy for improving therapy of superficial bladder cancer

  • Published:
World Journal of Urology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Abou-Zeid C, Ratliff TL, Wiker H (1988) Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun 56:3046–3051

    Google Scholar 

  2. Aslanzadeh J, Brown EJ, Quillin SP, et al (1989) Characterization of soluble fibronectin binding to bacillus Calmette-Guérin. J Gen Microbiol 135:2735–2741

    Google Scholar 

  3. Brosman SA (1982) Experience with bacillus Calmette-Guérin in patients with superficial bladder cancer. J Urol 128:27–30

    Google Scholar 

  4. Brosman SA (1985) The use of bacilus Calmette-Guérin in the therapy of bladder cancer in situ. J Urol 134:36–41

    Google Scholar 

  5. Grinnell F, Billingham RE, Burgess L (1981) Distribution of fibronectin during wound healing in vivo. J Invest Dermatol 76:181–189

    Google Scholar 

  6. Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136:970–974

    Google Scholar 

  7. Hanna MG, Zbar B, Rapp HJ (1972) Histopathology of tumor regression after intralesional injection of Mycobacterium bovis: II. Comparative effects of vaccinia virus, oxalone, and turpentine. J Natl Cancer Inst 48:1697–1707

    Google Scholar 

  8. Herr HW, Pinsky CM, Whitmore WF, et al (1985) Experience with intravesical bacillus Calmetter Guérin therapy of superficial bladder tumors. Urology 25:119–123

    Google Scholar 

  9. Herr HW, Pinsky CM, Whitmore WF, et al (1986) Long-term effect of intravesical bacillus Calmetter-Guérin on flat carcinoma in situe of the bladder. J Urol 135:265–267

    Google Scholar 

  10. Hudson MA (1990) Correlation of fibronectin binding capacity and antitumor efficacy of BCG substrains (abstract). AUA

  11. Hudson MA, Catalona WJ, Ritchey JK, et al (1989) Choice of an optimal diluent for intravesical bacillus Calmette-Guérin administration. J Urol 142:1438–1441

    Google Scholar 

  12. Hudson MA, Ritchey JK, Catalona WJ, et al (1990) Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 50:3843–3847

    Google Scholar 

  13. Hudson MA, Yuan JJ, Catalona WJ, et al (1990) Adverse impact of fibrin clot inhibitors on intraversical bacillus Calmette-Guérin therapy for superficial bladder tumors. J Urol 1362–1364

  14. Kavoussi LR, Brown EJ, Ritchey JR, et al (1990) Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. J Clin Invest 85:62–67

    Google Scholar 

  15. Kelley DR, Haaff EO, Becich M, et al (1986) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guérin. J Urol 135:268–271

    Google Scholar 

  16. Lamm D, Stogdill V, Stogdill B, et al (1986) Complications of bacillus Calmette-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:272–274

    Google Scholar 

  17. Lamm DL, Thor DE, Stogdill UD, et al (1982) Bladder cancer immunotherapy. J Urol 128:931–935

    Google Scholar 

  18. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Galmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180–183

    Google Scholar 

  19. Mori K, Lamm DL, Crawford DE (1986) A trial of bacillus Calmette-Guérin versus Adriamycin in superficial bladder cancer: A southwest Oncology Group study. Urol Int 41:254–259

    Google Scholar 

  20. Pode D, Alon Y, Horowitz AT (1986) The mechanism of human bladder tumor implantation in an in vitro model. J Urol 136:482–486

    Google Scholar 

  21. Ratliff TL, Gillen DP, Catalona WF (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155–158

    Google Scholar 

  22. Ratliff TL, Palmer JO, McGarr JA, et al (1987) Intraversical bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guérin. Cancer Res 47:1762–1766

    Google Scholar 

  23. Ratliff TL, McGarr JA, Abou-Zeid C, et al (1988) Attachment of Mycobacterium to F-coated surfaces. J Gen Microbiol 134:1307–1313

    Google Scholar 

  24. Zbar B, Bernstein ID, Rapp JJ (1971) Suppression of tumor growth at the site of injection with living bacillus Calmette-Guérin. J Natl Cancer Inst 46:831–839

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This work was supported by USPHS grants CA 37926 (T.L.R.) and CA 44426 (T.L.R.) from the National Cancer Institute through the Bladder Cancer Project

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ratliff, T.L., Hudson, M.A. & Catalona, W.J. Strategy for improving therapy of superficial bladder cancer. World J Urol 9, 95–98 (1991). https://doi.org/10.1007/BF00184040

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00184040

Keywords

Navigation